Loading...
NPI 1457985251 · Houston, TX · Clinical Medical Laboratory
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Ixi Wellness Dallas LLC is a clinical medical laboratory provider located in Houston, Texas. This profile covers 1 Medicare and 5 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | Ixi Wellness Dallas LLC |
| Address | 10303 Northwest Fwy Ste 263 |
| City | Houston |
| State | TX |
| ZIP | 77092 |
| Taxonomy | Clinical Medical Laboratory |
| NPI Enumerated | March 2, 2020 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $7.6M |
| Medicaid | $1.6K |
IXI WELLNESS DALLAS LLC’s code mix and taxonomy identify it as a COVID-19 testing–focused clinical medical laboratory: the top-revenue code is K1034 (provision of nonprescription self‑administered, self‑collected COVID-19 tests), and the provider’s taxonomy is Clinical Medical Laboratory, which aligns with distribution and processing of diagnostic tests rather than broad ambulatory care services. This concentrated diagnostic focus is the dominant operational signal in the dataset.
Medicare revenue is concentrated entirely in a single test family: the precomputed top-3 Medicare codes account for 100.0% of Medicare revenue, and K1034 alone is reported with $7.8M revenue (100.0% of this provider's total Medicare revenue) over 646K claims at $12 avg paid/claim. That concentration means nearly all of the provider’s Medicare receipts derive from one service line.
Despite the large Medicare footprint, the provider’s overall payer mix is effectively single‑payer: total Medicare revenue is listed as $7.6M versus total Medicaid revenue of $1.6K, indicating Medicare is the overwhelming source of billed revenue while Medicaid activity is de minimis. The precomputed top-3 Medicaid codes also account for 100.0% of Medicaid revenue, reinforcing that Medicaid dollars are almost entirely tied to the same limited set of testing codes.
On national competitive standing for K1034, the provider ranks #64 of 30,143 providers (100th percentile) and is labeled an "extreme outlier," which signals an unusually large national volume for this specific nonprescription self‑test provisioning code. That rank establishes IXI WELLNESS DALLAS LLC as a major national participant for this particular service, far above typical national volume for K1034.
The Medicaid-side competitive picture is far more modest: K1034 ranks #18 of 77 in-state (78th percentile), described as typical and unremarkable within Texas, while several other in-state PCR/surveillance codes (U0003, U0005, U0004, G2023) appear with claim counts but $0 avg paid/claim and $0 revenue. This suggests the provider files a variety of SARS‑CoV‑2 testing codes for Medicaid recipients but generates meaningful Medicaid revenue only through K1034 at a very small dollar scale ($1.2K reported for K1034).
Payer reimbursement and volume patterns differ sharply: Medicare shows 646K claims for K1034 at $12 avg paid/claim, whereas Medicaid shows 1.2K claims for K1034 at $1 avg paid/claim. Those contrasts highlight both the volume skew (Medicare far larger) and material per‑claim payment differences between payers for the same code.
The provider’s NPI was enumerated on 2020-03-02 (~6 years ago), placing its formal registration near the start of the COVID-19 pandemic; combined with the dominant K1034 activity, this timing is consistent with an operation established or repurposed to serve high-volume COVID testing demand. The tenure plus the concentrated code mix suggests a business model oriented around large-scale test distribution/processing rather than diversified clinical laboratory services.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
1 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| K1034 | Provision of covid-19 test, nonprescription self-administered and self-collected use, fda approved, authorized or cleared, one test count | 645,970 | $10 | $7.8M |
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 1 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
1 rows
| CPT/HCPCS Code | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|
| K1034 | 10 | 2,490 | 450 | $10 | $117.8K |
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
5 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| K1034 | Provision of covid-19 test, nonprescription self-administered and self-collected use, fda approved, authorized or cleared, one test count | 1,180 | $1 | $1.2K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 30 | $0 | $0 |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 170 | $0 | $0 |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by… | 30 | $0 | $0 |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc,… | 200 | $0 | $0 |
How this provider's Medicaid billing volume and revenue compare to other Texas providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Texas median
5 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 210 | 340 | 400 | $50 | $553.5K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by… | 93 | 100 | 470 | $50 | $319.1K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc,… | 173 | 260 | 640 | $20 | $137.2K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 268 | 340 | 220 | $10 | $24.1K |
| K1034 | Provision of covid-19 test, nonprescription self-administered and self-collected use, fda approved, authorized or cleared, one test count | 18 | 80 | 340 | $1 | $1.5K |
Other providers in the same ZIP code as Ixi Wellness Dallas LLC, ranked by combined Medicare and Medicaid revenue.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.